Literature DB >> 19133819

Acquisition and cross-transmission of Staphylococcus aureus in European intensive care units.

Alexander L A Bloemendaal1, Ad C Fluit, Wouter M T Jansen, Menno R Vriens, Tristan Ferry, Laurent Argaud, Jose M Amorim, A C Resende, Alvaro Pascual, Lorena López-Cerero, Stefania Stefani, Giacomo Castiglione, Penelope Evangelopoulou, Sophia Tsiplakou, Inne H M Borel Rinkes, Jan Verhoef.   

Abstract

OBJECTIVE: To study the acquisition and cross-transmission of Staphylococcus aureus in different intensive care units (ICUs).
METHODS: We performed a multicenter cohort study. Six ICUs in 6 countries participated. During a 3-month period at each ICU, all patients had nasal and perineal swab specimens obtained at ICU admission and during their stay. All S. aureus isolates that were collected were genotyped by spa typing and multilocus variable-number tandem-repeat analysis typing for cross-transmission analysis. A total of 629 patients were admitted to ICUs, and 224 of these patients were found to be colonized with S. aureus at least once during ICU stay (22% were found to be colonized with methicillin-resistant S. aureus [MRSA]). A total of 316 patients who had test results negative for S. aureus at ICU admission and had at least 1 follow-up swab sample obtained for culture were eligible for acquisition analysis.
RESULTS: A total of 45 patients acquired S. aureus during ICU stay (31 acquired methicillin-susceptible S. aureus [MSSA], and 14 acquired MRSA). Several factors that were believed to affect the rate of acquisition of S. aureus were analyzed in univariate and multivariate analyses, including the amount of hand disinfectant used, colonization pressure, number of beds per nurse, antibiotic use, length of stay, and ICU setting (private room versus open ICU treatment). Greater colonization pressure and a greater number of beds per nurse correlated with a higher rate of acquisition for both MSSA and MRSA. The type of ICU setting was related to MRSA acquisition only, and the amount of hand disinfectant used was related to MSSA acquisition only. In 18 (40%) of the cases of S. aureus acquisition, cross-transmission from another patient was possible.
CONCLUSIONS: Colonization pressure, the number of beds per nurse, and the treatment of all patients in private rooms correlated with the number of S. aureus acquisitions on an ICU. The amount of hand disinfectant used was correlated with the number of cases of MSSA acquisition but not with the number of cases of MRSA acquisition. The number of cases of patient-to-patient cross-transmission was comparable for MSSA and MRSA.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19133819     DOI: 10.1086/593126

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  14 in total

Review 1.  Systematic review of measurement and adjustment for colonization pressure in studies of methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, and clostridium difficile acquisition.

Authors:  Adebola O Ajao; Anthony D Harris; Mary-Claire Roghmann; J Kristie Johnson; Min Zhan; Jessina C McGregor; Jon P Furuno
Journal:  Infect Control Hosp Epidemiol       Date:  2011-05       Impact factor: 3.254

2.  Measurement and Impact of Staphylococcus aureus Colonization Pressure in Households.

Authors:  Marcela Rodriguez; Patrick G Hogan; Melissa Krauss; David K Warren; Stephanie A Fritz
Journal:  J Pediatric Infect Dis Soc       Date:  2013-02-11       Impact factor: 3.164

3.  Colonization pressure as a risk factor of ICU-acquired multidrug resistant bacteria: a prospective observational study.

Authors:  J Masse; A Elkalioubie; C Blazejewski; G Ledoux; F Wallet; J Poissy; S Preau; S Nseir
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-12-20       Impact factor: 3.267

Review 4.  Transmission pathways of multidrug-resistant organisms in the hospital setting: a scoping review.

Authors:  Natalia Blanco; Lyndsay M O'Hara; Anthony D Harris
Journal:  Infect Control Hosp Epidemiol       Date:  2019-03-06       Impact factor: 3.254

5.  The potential regional impact of contact precaution use in nursing homes to control methicillin-resistant Staphylococcus aureus.

Authors:  Bruce Y Lee; Ashima Singh; Sarah M Bartsch; Kim F Wong; Diane S Kim; Taliser R Avery; Shawn T Brown; Courtney R Murphy; S Levent Yilmaz; Susan S Huang
Journal:  Infect Control Hosp Epidemiol       Date:  2012-12-18       Impact factor: 3.254

6.  MRSA in a large German University Hospital: Male gender is a significant risk factor for MRSA acquisition.

Authors:  Markus Kupfer; Lutz Jatzwauk; Stephan Monecke; Jana Möbius; Axel Weusten
Journal:  GMS Krankenhhyg Interdiszip       Date:  2010-09-21

Review 7.  MRSA prevalence in European healthcare settings: a review.

Authors:  Madeleine Dulon; Frank Haamann; Claudia Peters; Anja Schablon; Albert Nienhaus
Journal:  BMC Infect Dis       Date:  2011-05-20       Impact factor: 3.090

8.  Whole-genome sequencing shows that patient-to-patient transmission rarely accounts for acquisition of Staphylococcus aureus in an intensive care unit.

Authors:  James R Price; Tanya Golubchik; Kevin Cole; Daniel J Wilson; Derrick W Crook; Guy E Thwaites; Rory Bowden; A Sarah Walker; Timothy E A Peto; John Paul; Martin J Llewelyn
Journal:  Clin Infect Dis       Date:  2013-12-12       Impact factor: 9.079

9.  Transmission of Staphylococcus aureus between health-care workers, the environment, and patients in an intensive care unit: a longitudinal cohort study based on whole-genome sequencing.

Authors:  James R Price; Kevin Cole; Andrew Bexley; Vasiliki Kostiou; David W Eyre; Tanya Golubchik; Daniel J Wilson; Derrick W Crook; A Sarah Walker; Timothy E A Peto; Martin J Llewelyn; John Paul
Journal:  Lancet Infect Dis       Date:  2016-11-16       Impact factor: 25.071

10.  The durability of examination gloves used on intensive care units.

Authors:  Nils-Olaf Hübner; Anna-Maria Goerdt; Axel Mannerow; Ute Pohrt; Claus-Dieter Heidecke; Axel Kramer; Lars Ivo Partecke
Journal:  BMC Infect Dis       Date:  2013-05-20       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.